Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
about
CD33 expression and P-glycoprotein-mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapyThe clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemiaClinicopathological and prognostic characteristics of CD33-positive multiple myeloma.A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.Tumour-targeted chemotherapy with immunoconjugates of calicheamicin.CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.The role of gemtuzumab ozogamicin in acute leukaemia therapy.Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicinAnti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia.Immunotherapy: a useful strategy to help combat multidrug resistance.Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia.CMC-544 (inotuzumab ozogamicin), an anti-CD22 immuno-conjugate of calicheamicin, alters the levels of target molecules of malignant B-cells.Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.Efficacy of gemtuzumab ozogamicin on ATRA- and arsenic-resistant acute promyelocytic leukemia (APL) cells.Multidrug resistance reversal properties and cytotoxic evaluation of representatives of a novel class of HIV-1 protease inhibitors.P-glycoprotein (P-gp) and multidrug resistance-associated protein 1 (MRP1) are induced by arsenic trioxide (As(2)O(3)), but are not the main mechanism of As(2)O(3)-resistance in acute promyelocytic leukemia cells.Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin.
P2860
Q24678297-64F2E139-2EB8-4E60-8AD7-703E44CECBC5Q26783425-50582345-EB89-48BE-81BC-3155F74F638FQ33371875-7CA1F3B1-8C89-4C18-90C9-DAB883C01463Q33692521-18742F3C-3AAC-424E-8D7D-0411F37B318BQ35873771-B2F1E1BD-64D2-4DB8-9332-61E0C24AA967Q35980938-AAC13637-9BC5-422C-AEFA-9D536F3211D3Q36367816-948A1CBA-612C-41B6-9412-1B87754B55E0Q36932014-5CA3DC0C-4493-4A02-8909-2CC07126652CQ37381414-077D510A-B462-42D7-B0D1-7E25281C57D9Q38000768-81DFCFA2-B7A8-4D52-9BF7-33EA942E7A57Q38109541-E37409C2-3C79-47F4-A67A-3D63D518E73EQ38355000-54D9E8A9-E9B1-4CC4-90E6-C77464E6723DQ38646986-055127B9-A511-4E8F-A2BF-1F7BF8288E01Q39506455-43CDE976-5E36-4DB4-B474-399C4E97382EQ39635266-9493D3ED-724D-4279-AED4-D1B4D3B301EAQ44368794-3AD676D1-11E8-485D-882F-6430A5D5CB54Q45236184-A12F3BDE-BE7C-42B4-8173-EB48A55F8A6BQ54329544-A8204271-60EB-4169-8116-1D26581AD9CE
P2860
Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Reduced effect of gemtuzumab o ...... ultidrug resistance modifiers.
@ast
Reduced effect of gemtuzumab o ...... ultidrug resistance modifiers.
@en
type
label
Reduced effect of gemtuzumab o ...... ultidrug resistance modifiers.
@ast
Reduced effect of gemtuzumab o ...... ultidrug resistance modifiers.
@en
prefLabel
Reduced effect of gemtuzumab o ...... ultidrug resistance modifiers.
@ast
Reduced effect of gemtuzumab o ...... ultidrug resistance modifiers.
@en
P2093
P356
P1433
P1476
Reduced effect of gemtuzumab o ...... ultidrug resistance modifiers.
@en
P2093
A Takeshita
M Kobayashi
M Tanimoto
P2888
P304
P356
10.1038/SJ.LEU.2402459
P577
2002-05-01T00:00:00Z
P5875
P6179
1049179947